Open AccessSaikosaponin-d suppresses cell growth in renal cell carcinoma through EGFR/p38 signaling pathway
Author(s) -
Changjie Cai,
H Zhang,
Yurong Ou,
Yunyun Jiang,
Dequan Zhong,
Huiling Qi,
Qiang Dang
Publication year - 2017
Publication title -
neoplasma
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.628
H-Index - 50
eISSN - 1338-4317
pISSN - 0028-2685
DOI - 10.4149/neo_2017_405
Subject(s) - apoptosis , cell growth , cell cycle , cell cycle checkpoint , flow cytometry , cancer research , cell , mtt assay , microbiology and biotechnology , chemistry , cell culture , signal transduction , biology , biochemistry , genetics
The study aimed to explore the effect of Saikosaponin-d (SSd) and its underlying mechanism on cell growth inhibition as well as induction of apoptosis and cell cycle arrest in renal cell carcinoma (RCC). MTT assay and colony formation assay were employed in this study, with the results indicating that RCC cells proliferation was inhibited by SSd at different doses. Analysis by flow cytometry revealed that RCC cell proliferation inhibitory effect of SSd was achieved by inducing apoptosis and cell cycle arrest at G0/G1 phase via up-regulation of p53. As compared to the control group, SSd can significantly inhibit the growth of 769-P and 786-O cell lines and induce apoptosis and cell cycle arrest. The mechanism exploration demonstrated that inhibiting the activation of EGFR/p38 signaling pathways was the molecular basis of SSd's biological effects such as inducing apoptotic death, inhibiting cell growth as well as up-regulating p53 expression in human RCC cells. In conclusion, our data suggest that SSd may serve as a promising intervention for chemopreventive or chemotherapeutic treatment for patients with RCC.